Literature DB >> 24871497

Comment on "Pain in people living with HIV/AIDS: a systematic review (Parker et al. 2014)".

Richard Harding1, Lorraine Sherr2.   

Abstract

Entities:  

Mesh:

Year:  2014        PMID: 24871497      PMCID: PMC4037537          DOI: 10.7448/IAS.17.1.19096

Source DB:  PubMed          Journal:  J Int AIDS Soc        ISSN: 1758-2652            Impact factor:   5.396


× No keyword cloud information.
Dear Editors, We were pleased to see the systematic review of pain prevalence and management in the Journal of the International AIDS Society [1]. The clinical and research neglect of pain among people living with HIV is a cause of great concern [2], especially as evidence demonstrates that it can be effectively controlled [3]. There are a number of important reasons as to why pain among people living with HIV should be a central clinical and public health concern, an aspect that was not elaborated in the recent review. There is evidence that pain and symptom burden are associated first with sexual risk taking [4], second with poor adherence to antiretroviral therapy (ART) [5], third with treatment switching [6], fourth with viral rebound [7], fifth with poor quality of life [8] and sixth with suicidal ideation [9]. There are several reasons for this lack of attention to pain, including patients' belief that pain must be endured with an HIV diagnosis, physicians' lack of recognition of pain and their reluctance to enquire, document, monitor and treat pain symptoms [10]. Evidence suggests that HIV physicians detect only a third of patients' problems during clinical encounters [11,12]. In low- and middle-income countries, recent evidence has revealed poor availability of analgesics in pharmacies of HIV care facilities, not just with opioids but also with “step 1” analgesics such as paracetemol, with stockouts of analgesics being common [13]. The authors suggest that broader concepts of pain might be useful in this population. New evidence has identified the constituent components of self-reported pain, which reflect the physical, psychological and social dimensions of pain experienced by people living with HIV, especially in low- and middle-income countries [14]. We would also like to note that the search strategy employed by the authors in the March 2012 review fell short of retrieving and reporting some key data [1]. Specifically, data on pain among ART patients in South Africa found a seven-day period prevalence of 51.2% [15]; a study of newly diagnosed people in Uganda reported a seven-day period prevalence of 76% [16]; a study of HIV outpatients in Tanzania reported 41.4% point prevalence [17]; a UK community sample of men found a seven-day period prevalence of 42.6% [18], whereas a UK outpatient sample reported a seven-day period prevalence of 53.2% [19]. These data that were missed in the review go some way in addressing the focus of studies on high-income countries, and also a number of these additional papers address the issue of pain for those on ART, which has been a concern since the advent of new treatments [20]. Given the agreement across studies of high pain prevalence, we call for intervention studies to improve assessment and control of pain. We also call for studies to address the issue of pain among children, which was beyond the objectives of the present review, but has been noted as an area of great need but little evidence in a review of pediatric palliative care in sub-Saharan Africa [21].
  21 in total

1.  Pain and symptom control in HIV disease: under-researched and poorly managed.

Authors:  Richard Harding; Philippa Easterbrook; Natalya Dinat; Irene J Higginson
Journal:  Clin Infect Dis       Date:  2005-02-01       Impact factor: 9.079

2.  Clinical importance of provider-reported HIV symptoms compared with patient-report.

Authors:  A C Justice ; C H Chang ; L Rabeneck; R Zackin
Journal:  Med Care       Date:  2001-04       Impact factor: 2.983

3.  Physical and psychological symptoms and risk of virologic rebound among patients with virologic suppression on antiretroviral therapy.

Authors:  Fiona C Lampe; Richard Harding; Colette J Smith; Andrew N Phillips; Margaret Johnson; Lorraine Sherr
Journal:  J Acquir Immune Defic Syndr       Date:  2010-08       Impact factor: 3.731

4.  Behavioral surveillance study: sexual risk taking behaviour in UK HIV outpatient attendees.

Authors:  Richard Harding; Claudine Clucas; Fiona C Lampe; Sally Norwood; Heather Leake Date; Martin Fisher; Margaret Johnson; Simon Edwards; Jane Anderson; Lorraine Sherr
Journal:  AIDS Behav       Date:  2012-08

Review 5.  Does palliative care improve outcomes for patients with HIV/AIDS? A systematic review of the evidence.

Authors:  R Harding; D Karus; P Easterbrook; V H Raveis; I J Higginson; K Marconi
Journal:  Sex Transm Infect       Date:  2005-02       Impact factor: 3.519

6.  Patient and provider-reported symptoms in the post-cART era.

Authors:  E J Edelman; K Gordon; A C Justice
Journal:  AIDS Behav       Date:  2011-05

7.  Integration of palliative care throughout HIV disease.

Authors:  Victoria Simms; Irene J Higginson; Richard Harding
Journal:  Lancet Infect Dis       Date:  2012-06-11       Impact factor: 25.071

8.  Improving HIV management in sub-Saharan Africa: how much palliative care is needed?

Authors:  K Collins; R Harding
Journal:  AIDS Care       Date:  2007-11

Review 9.  Pediatric palliative care in sub-saharan Africa: a systematic review of the evidence for care models, interventions, and outcomes.

Authors:  Richard Harding; Rene Albertyn; Lorraine Sherr; Liz Gwyther
Journal:  J Pain Symptom Manage       Date:  2013-08-21       Impact factor: 3.612

Review 10.  Pain in people living with HIV/AIDS: a systematic review.

Authors:  Romy Parker; Dan J Stein; Jennifer Jelsma
Journal:  J Int AIDS Soc       Date:  2014-02-18       Impact factor: 5.396

View more
  1 in total

1.  Symptom Clusters in People Living with HIV Attending Five Palliative Care Facilities in Two Sub-Saharan African Countries: A Hierarchical Cluster Analysis.

Authors:  Katrien Moens; Richard J Siegert; Steve Taylor; Eve Namisango; Richard Harding
Journal:  PLoS One       Date:  2015-05-12       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.